Synthesis and antibacterial activity of a series of novel dihydrobenzofuranols

T. D. Venu¹, B. S. Sudha², S. Satish³, S. Shashikanth¹, K. A. Raveesha³*

¹ Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India ² Department of Chemistry, Yuvaraja's College, University of Mysore, Mysore 570 005, India ³ Department of Studies in Microbiology, University of Mysore, Manasagangotri, Mysore 570 006, India

Received April 15, 2008; Revised February 3, 2009

A facile synthesis of solely dihydrobenzofuranols was achieved by irradiation of 2-alkoxy substituted benzophenones in acetonitrile. The antibacterial activities of the resulting compounds were studied against 12 human pathogens. All the compounds showed significant growth inhibition at concentration of $50~\mu g/mL$. The halogen substituted compounds were most active whereupon one of the compounds showed stronger inhibition towards all the strains than the antibitioes bacitracin, ciprofloxacin and gentamicin.

Key words: photochemical synthesis, dihydrobenzofuranols, antibacterial activity.

INTRODUCTION

The chemistry of dihydrobenzofurans has recently drawn considerable attention from chemical, physiological and pharmacological point of view [1–4]. Intramolecular hydrogen abstractions are among some of the best studied reactions in organic photochemistry. The most prevalent example involves abstraction of a γ-hydrogen, i.e., the Norrish Type II reaction [5]. However, a number of cases of both δ - and ϵ -hydrogen abstraction has also been reported [6]. These reactions are object of recent interest because they provide useful insight into ketone photochemistry and biradical behaviour and have potential synthetic application in the construction of five and six membered rings [7]. One example of a δ -hydrogen abstraction, which has found some applications in synthesis, is the photocyclization of 2-alkoxy substituted benzophenones to dihydrobenzofuranols (Scheme 1).

Literature survey on the structure-activity relationship among dihydrobenzofuranol analogues revealed that no efforts were directed towards the study of their antibacterial activities when different substituents were introduced in the aromatic rings. We supposed that varying the substituents in the aromatic ring might affect the antibacterial activity.

In this communication, we report a facile synthesis of a series of new dihydrobenzofuranols with different combinations of substituents in their aromatic rings and evaluation of their antibacterial activity against 12 human pathogens. The synthesis was based on cyclization of 1,5-biradicals, generated by

irradiation of substituted 2-alkoxy benzophenones.

CHEMISTRY

The synthesis of the title compounds is outlined in Scheme 1.

$$\begin{array}{c} \text{OCH}_{3} \\ \text{R}_{1} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{Ia-h} \\ \end{array} \begin{array}{c} \text{CH}_{3}\text{Br} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{2a-h} \\ \end{array} \begin{array}{c} \text{Nydrogen abstraction} \\ \text{R}_{4} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{2a-h} \\ \end{array} \begin{array}{c} \text{OCH}_{3} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{2a-h} \\ \end{array} \begin{array}{c} \text{Nydrogen abstraction} \\ \text{R}_{4} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{R}_{2} \\ \text{R}_{3} \\ \end{array} \begin{array}{c} \text{OCH}_{2} \\ \text{R}_{4} \\ \text{R}_{4} \\ \text{R}_{5} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{R}_{4} \\ \text{R}_{5} \\ \text{R}_{2} \\ \text{R}_{3} \\ \text{R}_{4} \\ \text{R}_{5} \\ \text{R}_{6} \\ \text{R}_{7} \\ \text{R}_{8} \\ \text{R}_{7} \\ \text{R}_{7} \\ \text{R}_{8} \\ \text{R}_{8}$$

^{*} To whom all correspondence should be sent:

E-mail: karaveesha@gmail.com

^{© 2009} Bulgarian Academy of Sciences, Union of Chemists in Bulgaria

2-Hydroxy substituted benzophenones 1a-h, were synthesized as it was previously described [8]. The substrates for photocyclization, the 2-alkoxy substituted benzophenones 2a-h, were synthesized in good yields by the reaction of 1a-h with methyl iodide in the presence of anhydrous potassium carbonate (Scheme 1). Irradiation of degassed solutions of 2a-h in acetonitrile was conducted at ambient temperatures (~ 33°C) and 365 nm, 400 W high-pressure mercury lamp with Pyrex filter. The products 3a-h were characterized by IRS, NMR and elemental analysis.

RESULTS AND DISCUSSION

Widespread use of antibiotics is thought to have spurred evolutionary adaptations that enable bacteria to survive these powerful drugs. The combat with the bacterial resistance demands a search for alternative newer molecules. For this reason, the eight new dihydrobenzofuranols **3a–f** synthesized in this

study, were screened in regard to their antibacterial activities. Their growth inhibitory activity was tested against nine Gram-positive and three Gramnegative bacteria (Table 1). Three of the compounds **3e**, **3f** and **3h** were shown to be highly potent antibacterial agents. Their antibacterial activity was much stronger than that of ciprofloxacin, which is a powerful antibiotic used to overcome bacterial infections.

CONCLUSION

Our study shows a strong evidence for the antibacterial activity of halo substituted dihydrobenzofuranols. These compounds exhibited stronger growth inhibitory activity than the reference compounds. The presence of methyl groups in ring A and B was not favourable. The compounds are very good candidates for further investigation on their therapeutic effect for management of bacterial infections.

Table 1. Antibacterial activity measured as zone of inhibition (mm) of eight newly synthesized dihydrobenzofuranols (3a-h) (50 μg/mL) against human pathogenic bacteria.

Pathogens	3a	3b	3c	3d	3e	3f	. 3g	3h	Bacitracin	Ciprofloxacin	Gentamicin
Bacillus subtilis	12.50	18.66	28.50	19.50	29.50	33.66	22.66	28.50	0.00	19.62	12.66
MTCC441	± 0.39	± 0.22	± 0.27	± 0.25	± 0.27	± 0.15	± 0.06	± 0.25	± 0.00	± 0.18	± 0.12
Escherichia	15.16	20.00	29.50	26.66	31.50	34.50	28.50	30.66	0.00	10.00	10.25
coli	\pm 0.22	± 0.00	± 0.25	± 0.66	± 0.17	± 0.27	± 0.27	± 0.66	± 0.00	± 0.00	± 0.14
MTCC443											
Klebsiella	09.50	17.33	21.50	17.50	23.66	25.38	19.83	22.83	0.00	20.25	11.75
pneumoniae	± 0.28	± 0.16	± 0.17	± 0.19	± 0.15	± 0.18	± 0.20	± 0.20	± 0.00	± 0.16	± 0.16
MTCC109											
Proteus	18.00	15.50	22.66	19.83	21.50	22.16	21.66	20.83	0.00	18.25	08.50
mirabilis	± 0.00	± 0.27	± 0.15	± 0.14	± 0.27	± 0.12	± 0.25	± 0.20	± 0.00	± 0.16	± 0.16
MTCC1429		4.									
Pseudomonas	10.00	16.50	34.50	17.50	35.38	36.50	19.75	32.66	0.00	34.25	12.63
aeruginosa	± 0.00	± 0.23	± 0.13	± 0.25	± 0.18	± 0.12	± 0.16	± 0.25	± 0.00	± 0.16	± 0.16
MTCC1688		A	Q. 1								
Salmonella	11.50	18.50	29.50	20.66	30.16	32.66	22.83	29.50	0.00	27.75	15.25
paratyphi A	± 0.18	± 0.21	± 0.25	± 0.66	± 0.12	± 0.25	± 0.14	± 0.17	± 0.00	± 0.16	± 0.16
MTCC735											
Salmonella	18.83	20.50	27.83	22.83	29.50	31.83	24.66	28.50	0.00	20.25	17.75
typhi	± 0.14	± 0.19	± 0.20	± 0.20	± 0.12	± 0.14	± 0.15	± 0.19	± 0.00	± 0.16	± 0.16
MTCC733		No.									
Salmonella	12.33	18.50	25.50	19.33	26.66	28.66	22.50	25.66	0.00	18.75	16.00
typhimurium	± 0.15	± 0.20	± 0.27	± 0.17	± 0.25	± 0.06	± 0.25	± 0.12	± 0.00	± 0.31	± 0.31
MTCC98	host ^{ot}										
Shigella 🦻	10.33	13.50	19.66	14.83	21.83	24.50	18.66	20.66	0.00	27.63	11.38
flexneri	± 0.16	± 0.27	± 0.11	± 0.20	± 0.14	± 0.25	± 0.66	± 0.11	± 0.00	± 0.18	± 0.18
MTCC1457											
Shigella sonnei	08.50	12.66	21.50	13.66	23.66	29.83	23.83	22.50	0.00	21.75	15.25
MTCC 2957	± 0.27	± 0.14	± 0.17	± 0.25	± 0.06	± 0.14	± 0.20	± 0.13	± 0.00	± 0.16	± 0.16
Staphylococcus	19.00	24.00	35.33	23.50	34.50	35.50	25.83	33.66	26.75	18.13	24.63
aureus	± 0.00	± 0.22	± 0.18	± 0.17	± 0.25	± 0.13	± 0.20	± 0.15	± 0.84	± 0.48	± 0.48
MTCC 737											
Streptococcus	15.50	21.50	33.66	20.66	32.83	33.12	27.66	31.83	10.00	10.00	12.50
faecalis	± 0.33	± 0.30	± 0.11	± 0.66	± 0.14	± 0.19	± 0.25	± 0.14	± 0.00	± 0.00	± 0.00
MTCC459											

Zone of inhibition (Mean of six replicates \pm standard error). p < 0.05.

EXPERIMENTAL

Chemistry

Chemicals were purchased from Aldrich Chemical Co. Thin layer chromatography (TLC) was performed on silica gel plates with visualization under UV-light. Melting points were determined on a Thomas Hoover capillary melting point apparatus with a digital thermometer and were not corrected. The IR spectra were recorded in nujol on FT-IR Shimadzu 8300 spectrometer. ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃ at 300 and 100 MHz, respectively. Chemical shifts were in parts per million downfield from tetramethylsilane. *J* constants were in Hz. Elemental analysis data are within 0.4% deviation of the calculated value.

General procedure for synthesis of substituted 2-alkoxybenzophenones **2a–2h**

Bromomethane (1.9 g, 0.02 mol) was added to a solution of (2-hydroxy-5-methylphenyl)-4-methyl phenyl methanone **1a** (5.21 g, 0.02 mol) and anhydrous potassium carbonate (2.8 g, 0.02 mol) in dry acetone (50 ml). The solution was refluxed for 18 h, cooled down and then evaporated to dryness. The residue was treated with ice water to remove potassium carbonate and extracted with (ethyl) ether (3×50 ml). The organic layer was washed with 10% sodium hydroxide solution (3×30ml) and water (3×30 ml), dried over anhydrous sodium sulphate and evaporated. The obtained crude solid was recrystallized from ethanol to give the pure compounds 2a-2h.

Compound **2a:** [9] yield 83%, m.p. 160–162°C; IRS (nujol): 1658 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ 2.25 (s, 3H, Ar–CH₃), 2.32 (s, 3H, Ar–CH₃), 3.6 (s, 3H, OCH₃), 6.7–7.7 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 20.9 (q), 56.0 (q), 113.7 (d), 123.3 (s), 128.9 (d), 129.9 (s), 130 (d), 131.8 (d), 133.9 (d), 134.8 (s), 141.4 (s), 160.6 (s), 187.0 (s). Anal. Calcd for $C_{16}H_{16}O_2$ (240); C 80.0; H 6.67%. Found: C 80.12; H 6.63%.

Compound **1a–h:** [9] yield 75%, m.p. $55-58^{\circ}$ C; IRS (nujol): 1660 cm^{-1} (C=O); $^{1}\text{H NMR}$ (CDCl₃) δ 2.23 (s, 3H, Ar–CH₃), 3.55 (s, 3H, OCH₃), 6.65–7.5 (bm, 7H, Ar–H); $^{13}\text{C NMR}$ (CDCl₃): δ 20.9 (q), 56.0 (q), 113.7 (d), 123.3 (s), 126.8 (s), 129.7 (s), 131.5 (d), 131.8 (d), 132.3 (d), 133.9 (d), 136.8 (s), 160.6 (s), 187.0 (s). Anal. Calcd for C₁₅H₁₃BrO₂ (305); C 59.02; H 4.26; Br 26.23%. Found: C 58.95; H 4.25; Br 26.21%.

Compound **2c:** [9] yield 71%, m.p. 150–152°C; IRS (nujol): 1659 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ 2.22 (s, 3H, Ar–CH₃), 3.5 (s, 3H, OCH₃), 6.6–7.8 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 20.9 (q), 56.0

(q), 113.7 (d), 123.3 (s), 127.7 (d), 129.6 (d),129.7 (s), 131.8 (d), 133.9 (s), 133.9 (d), 134.0 (d), 135.8 (s), 139.6 (s), 160.6 (s), 187.0 (s). Anal. Calcd for $C_{15}H_{12}Cl_2O_2$ (295); C 61.02; H 4.07; Cl 24.07%. Found: C 60.89; H 4.02; Cl 24.05%.

Compound **2d:** yield 83%, m.p. $151-153^{\circ}$ C; IRS (nujol): 1665 cm^{-1} (C=O); ${}^{1}\text{H NMR}$ (CDCl₃) δ 2.33 (s, 3H, Ar–CH₃), 3.65 (s, 3H, OCH₃), 6.75–7.6 (bm, 7H, Ar–H); ${}^{13}\text{C NMR}$ (CDCl₃): δ 20.9 (q), 56.0 (q), 113.7 (d), 123.3 (s), 128.9 (d), 129.9 (s), 130 (d), 131.8 (d), 133.9 (d), 134.8 (s), 141.4 (s), 160.6 (s), 187.0 (s). Anal. Calcd for $C_{15}H_{13}\text{ClO}_2$ (260.72); C 69.10; H 5.03; Cl 13.60%. Found: C 69.12; H 5.01; Cl 13.59%.

Compound **2e:** yield 83%, m.p. 138–141°C; IRS (nujol): 1668 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ 3.7 (s, 3H, OCH₃), 6.77–7.64 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 56.0 (q), 115.2 (d), 124.8 (s), 125.8 (s), 128.6 (d), 131.5 (d), 131.6 (d), 133.6 (d), 135.9 (s), 137.5 (s), 161.7 (s), 187.0 (s). Anal. Calcd for C₁₄H₁₀Cl₂O₂ (281.13); C 59.81; H 3.59; Cl 25.22%. Found: C 59.79; H 3.63; Cl 25.20%.

Compound **2f:** yield 83%, m.p. $132-134^{\circ}$ C; IRS (nujol): 1670 cm^{-1} (C=O); ^{1}H NMR (CDCl₃) δ 3.68 (s, 3H, OCH₃), 6.85–7.65 (bm, 7H, Ar–H); ^{13}C NMR (CDCl₃): δ 56.0 (q), 115.4 (d), 118.1 (d), 120.2 (d), 125.0 (s), 128.6 (d), 131.5 (d), 135.9 (s), 137.5 (s), 154.1 (s), 159.2 (s), 187.0 (s). Anal. Calcd. for C₁₄H₁₀ClFO₂ (264.68); C 63.53; H 3.81; Cl 13.39; F 7.18%. Found: C 63.55; H 3.83; Cl 13.37; F 7.16%.

Compound **2g:** yield 83%, m.p. 143–145°C; IRS (nujol): 1667 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ 2.3 (s, 3H, Ar–CH₃), 3.67 (s, 3H, OCH₃), 6.71–7.47 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 20.9 (q), 56.0 (q), 115.4 (d), 118.1 (d), 120.2 (d), 125.0 (s), 128.9 (d), 130.0 (d), 134.8 (s), 141.4 (s), 154.1 (s), 159.2 (s), 187.0 (s). Anal. Calcd for C₁₅H₁₃FO₂ (244.26); C 73.76; H 5.36; F 7.78%. Found: C 73.78; H 5.33; F 7.76%.

Compound **2h:** yield 79%, m.p. 149–151°C; IRS (nujol): 1675 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ 3.6 (s, 3H, OCH₃), 6.7–7.7 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 56.0 (q), 115.1 (s), 116.0 (d), 125.6 (s), 128.6 (d), 131.5 (d), 134.4 (d), 135.9 (s), 136.5 (d),137.5 (s), 162.6 (s), 187.0 (s). Anal. Calcd for $C_{14}H_{10}BrClO_2$ (325.59); C 51.65; H 3.10; Br 25.54.18; C1 10.89%. Found: C 51.63; H 3.12; Br 25.55, Cl 10.87%.

General procedure for the synthesis of dihydrobenzofuranols **3a–3h**

The starting compounds **2a–2h** (15 mmol) were dissolved in acetonitrile (50 mL) and deoxygenated by bubbling nitrogen gas for 1 h and then irradiated

for 4–20 h. After the completion of the reaction (monitored by TLC), the solvent was evaporated under reduced pressure at 40°C. The residue was subjected to column chromatography on silica gel with eluent mixture hexane:chloroform:acetone (7:3:1) to give pure compounds **3a–3h**.

Compound **3a:** [9] yield 77%, m.p. 156–157°C; IRS (nujol): 3410 cm⁻¹ (OH); ¹H NMR (CDCl₃): δ 2.4 (s, 3H, Ar–CH₃), 2.5 (s, 3H, Ar–CH₃), 3.9 (s, 1H, C₂–H), 4.3 (s, 1H, C₂–H), 6.0–6.2 (bs, 1H, OH), 7.2–8.0 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 20.9 (q), 21.2 (q), 80.5 (t), 88.3 (s), 114.6 (d), 127.3 (d), 128.3 (d), 128.6 (s), 129.7 (d), 129.8 (s), 135.2 (s), 140.0 (s), 155.7 (s). Anal. Calcd for C₁₆H₁₆O₂ (240); C 80.0; H 6.67%. Found: C 79.60; H 6.62%.

Compound **3b:** [9] yield 72%, m.p. 155–157°C; IRS (nujol): 3420 cm⁻¹ (OH); H NMR (CDCl₃): δ 2.4 (s, 3H, Ar–CH₃), 3.8 (s, 1H, C₂–H), 4.4 (s, 1H, C₂–H), 6.0–6.2 (bs, 1H, OH), 7.2–8.0 (bm, 7H, Ar–H); H CNMR (CDCl₃): δ 21.2 (q), 80.5 (t), 88.3 (s), 114.6 (d), 120.6 (s), 127.3 (d), 128.3 (d), 128.6 (d), 129.7 (d), 129.8 (s), 155.7 (s). Anal. Calcd for C₁₅H₁₃BrO₂ (305); C 59.02; H 4.26; Br 26.23%. Found: C 59.0; H 4.21; Br 26.18%.

Compound 3c: [9] yield 81%, m.p. 158–159°C; IRS (nujol): 3415 cm^{-1} (OH); ^{1}H NMR (CDCl₃): δ 2.4 (s, 3H, Ar–CH₃), 3.9 (s, 1H, C₂–H), 4.4 (s, 1H, C₂–H), 6.0–6.3 (bs, 1H, OH), 7.2–8.0 (bm, 7H, Ar–H); ^{13}C NMR (CDCl₃): δ 21.2 (q), 78.7 (s), 80.0 (t), 88.3 (s), 114.6 (d), 127.3 (d), 127.8 (d), 127.9 (d), 128.5 (d), 128.6 (s), 129.7 (d), 129.8 (s), 134.1 (s), 134.7 (s), 144.8 (s), 155.7 (s). Anal. Calcd for C₁₅H₁₂Cl₂O₂ (295); C 61.02; H 4.07; Cl 24.07%. Found: C 61.0; H 4.08; Cl 23.04%.

Compound **3d:** yield 75%, m.p. 160–162°C; IRS (nujol): 3430 cm⁻¹ (OH); ¹H NMR (CDCl₃): δ 2.35 (s, 3H, Ar–CH₃), 3.8 (s, 1H, C₂–H), 4.2 (s, 1H, C₂–H), 6.1–6.3 (bs, 1H, OH), 7.0–7.8 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 21.2 (q), 80.5 (t), 88.3 (s), 114.6 (d), 127.3 (d), 128.6 (s), 129.4 (d), 129.7 (d), 129.8 (s), 131.4 (s),141.1 (s), 155.7 (s). Anal. Calcd for $C_{15}H_{13}ClO_2$ (260.72); C 69.10; H 5.03; Cl 13.60%. Found: C 69.35; H 5.01; Cl 13.59%.

Compound **3e:** yield 78%, m.p. 165–167°C; IRS (nujol): 3425 cm⁻¹ (OH); ¹H NMR (CDCl₃): δ 3.9 (s, 1H, C₂–H), 4.3 (s, 1H, C₂–H), 6.2–6.4 (bs, 1H, OH), 7.3–7.9 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 80.5 (t), 87.5 (s), 116.1 (d), 125.9 (s), 127.0 (d), 129.4 (d), 129.5 (d), 129.8 (d), 130.1 (s), 131.3 (s), 141.1 (s), 156.8 (s). Anal. Calcd for $C_{14}H_{10}Cl_2O_2$ (281.13); C 59.81; H 3.59; Cl 25.22%. Found: C 59.79; H 3.57; Cl 25.21%.

Compound **3f:** yield 81%, m.p.. 151–153°C; IRS (nujol): 3435 cm^{-1} (OH); ^{1}H NMR (CDCl₃): δ 3.75 (s, 1H, C₂–H), 4.1 (s, 1H, C₂–H), 6.05–6.3 (bs, 1H,

OH), 7.2–7.85 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 80.5 (t), 88.0 (s), 113.6 (d), 116.0 (d), 116.3 (d), 129.4 (d), 129.5 (d), 129.8 (d), 130.3 (s), 131.3 (s), 141.1 (s), 154.2 (s), 154.3 (s). Anal. Calcd for C₁₄H₁₀ClFO₂ (264.68); C 63.53; H 3.81; Cl 13.39; F 7.18%. Found: C 63.55; H 3.84; Cl 13.31; F 7.17%.

Compound **3g:** yield 69%, m.p. 147–149°C; IRS (nujol): 3415 cm⁻¹ (OH); ¹H NMR (CDCl₃): δ 3.85 (s, 1H, C₂–H), 4.3 (s, 1H, C₂–H), 6.0–6.25 (bs, 1H, OH), 7.1–7.8 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 20.9 (q), 80.5 (t), 88.0 (s), 113.6 (d), 116.0 (d), 116.3 (d), 128.3 (d), 129.7 (d), 130.3 (s), 135.2 (s), 140.1 (s), 154.2 (s), 154.3 (s). Anal. Calcd for $C_{15}H_{13}FO_2$ (244.26); C 73.76; H 5.36; F 7.78%. Found: C 73.73; H 5.38; F 7.76%.

Compound **3h:** yield 67%, m.p. 159–160°C; IRS (nujol): 3420 cm⁻¹ (OH); ¹H NMR (CDCl₃): δ 3.75 (s, 1H, C₂–H), 4.3 (s, 1H, C₂–H), 6.05–6.3 (bs, 1H, OH), 7.25–8.05 (bm, 7H, Ar–H); ¹³C NMR (CDCl₃): δ 80.5 (t), 87.3 (s), 115.2 (s), 116.9 (d), 129.4 (d), 129.8 (d), 129.9 (d), 130.9 (s), 131.2 (s), 132.3 (d), 141.1 (s), 157.7 (s). Anal. Calcd for C₁₄H₁₀BrClO₂ (325.59); C 51.65; H 3.10; Br 24.54; Cl 10.89%. Found: C 51.63; H 3.08; Br 24.56; Cl 10.87%.

Antibacterial activity assay

The antibacterial activity was determined by agar diffusion method. The sterile medium (20 mL) was poured onto a 9 cm Petri plates. The medium was allowed to cool down in a sterile condition and plates were then inculcated with 1×10^5 cfu cultures of the tested bacteria. The concentration of bacterial cells in the suspension was adjusted to a minimum of 1×10° cfu/ml in nutrient broth solution. Agar cups of 5 mm diameter were made in the plates. Each test sample was dissolved in dimethyl formamide (DMF), 50 µL of the test solution containing 50 µg/mL of the test compound were placed in each cup. The plates were left to stay for an hour in order to facilitate the diffusion of the drug solution. Negative control samples were prepared using the same solvent (DMF) employed to dissolve the examined compounds [10]. Then the plates were incubated at 37°C for 24 h. The zone of inhibition (if any) against the used bacteria was measured in mm. Bacitracin and ciprofloxacin were used as positive reference to determine the sensitivity of each bacterial strain tested.

Acknowledgements: The authors express their sincere gratitude to University of Mysore, Mysore, for the laboratory facilities.

REFERENCES

- 1. H. Mallesha, N. D. Dinesh, K. S. Rangappa, S. Shashikanth, N. K. Lokanath, M. A. Sridhar, J. S. Prasad, *Indian J. Chem.*, Sect. B, **41**, 196 (2002).
- 2. R. S. Kusurkar, D. K. Bhosale, *Synth. Commun.*, **20**, 101 (1990).
- 3. P. Cagniant, D. Cagniant, in: Advances in Heterogeneous Chemistry, A. R. Katritzky, A. J. Boulton (eds), vol. 18, Academic Press, New York, 1975, p. 338
- 4. K. B. G. Torssell, in: Natural Product Chemistry, John Wiley and Sons Ltd., Great Britain, 1983, pp.

- 127, 155.
- 5. P. J. Wagner, Acc. Chem. Res., 4, 168 (1971).
- 6. P. J. Wagner, Acc. Chem. Res., 22, 83 (1989).
- 7. M. A. Aziz, J. V. Auping, M. A. Meador, *J. Org. Chem.*, **60**, 1303 (1995).
- 8. S. A. Khanum, S. K. Murari, S. Viswanath, S. Shashikanth, *Bioorg. Med. Chem. Lett.*, **15**, 4100 (2005).
- 9. S. Shashikanth, B. S. Sudha, S. A. Khanum, *Heteroat. Chem.*, **16**, 212 (2005).
- 10. Anonymous, Pharmacopoeia of India (The Indian Pharmacopoeia), 3rd Edn., Government of India, 1996.

СИНТЕЗ И АНТИМИКРОБНА АКТИВНОСТ НА НОВИ СЕРИИ ДИХИДРОБЕНЗОФУРАНОЛИ

Т. Д. Вену¹, Б. С. Судха², С. Сатиш³, С. Шашикант¹, К. А. Равееша³,*

¹ Департамент по химия, Университет на Майсур, Манасаганготри, Майсур 570006, Индия ² Департамент по химия, Колеж на Ювараджа, Университет на Майсур, Майсур 570005, Индия ³ Департамент по микробиология, Университет на Майсур, Манасаганготри, Майсур 570006, Индия

Постъпила на 15 април 2009 г.; Преработена на 3 февруари 2009 г.

(Резюме)

Лесна синтеза само на дихидробензофураноли е постигната чрез облъчване на 2-алкокси заместени бензофенони в ацетонитрил. Изследвана е антимикробната активност на получените съединения срещу 12 човешки патогени. Всички съединения показват значително задържане на растежа при концентрация от 50 µg/mL. Халоген-заместените съединения са по-активни, докато едно от съединенията показа по-силно инхибиране към всичките форми от антибиотиците бацитрацин, ципрофлоксацин и гентамицин.